4.7 Article

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database

Journal

BIOMEDICINES
Volume 11, Issue 8, Pages -

Publisher

MDPI
DOI: 10.3390/biomedicines11082162

Keywords

CAR-T-cells; axi-cel; immune-effector-cell-associated neurotoxicity syndrome; cytokine release syndrome; pharmacovigilance; EudraVigilance

Ask authors/readers for more resources

In this study, 2905 individual case safety reports (ICSRs) were evaluated, showing that approximately 80% of the reported adverse events related to axi-cel were serious, and approximately 20% did not fully resolve or resulted in death. The most frequently reported adverse events were nervous system disorders and immune system disorders, suggesting that axi-cel may be more neurotoxic than other CAR-T-cell therapies.
During pre-approval clinical trials, the safety of axi-cel, a second-generation CAR-T-cell therapy directed against CD19, which dramatically improved the prognosis of intractable B-cell lymphomas, has been investigated only in about 400 patients. Therefore, additional information on this issue is urgently needed. In the present paper, we evaluated the 2905 ICSRs with axi-cel as the suspected drug that had been uploaded in the EudraVigilance database from 1 January 2018 to 31 December 2022. About 80% of the reported adverse events were serious, and about 20% of them did not fully resolve or caused death. The adverse events most-frequently reported were Nervous system disorders (25.6%) and, among them, immune-effector-cell-associated neurotoxicity syndrome, followed by Immune system disorders (23.1%), General disorders and administration site conditions (12.0%), Blood and lymphatic system disorders (7.2%), and Infections and infestations (5.8%). Disproportionality analysis showed that the frequency of reported adverse events related to the nervous system was higher with axi-cel than with the other approved CAR-T-cells, except brexu-cel. In conclusion, real-world pharmacovigilance data showed that nervous system and immune system disorders are the adverse events most reported in axi-cel-related ICSRs and suggest that axi-cel could be more neurotoxic than other CAR-T-cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available